PMN

PMN

ProMIS Neurosciences Inc.

1.97 USD

Last updated Nov 29, 08:49 UTC

Yesterday HIGH

$1.31

Yesterday LOW

$1.16

52w HIGH

$8.95

52w LOW

$1.16

EPS

-0.19

PE

-10.37

Next Earnings

Mar 6, 2024

Overview News Government Trades

ProMIS Neurosciences Inc. stock is up 12.57% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 11 November’s closed higher than October.

N/A

Stock Exchange

-

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

promisneurosciences.com

Benzinga Newsdesk

Mon Jul 17, 2023

ProMIS Neurosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 117.4%
Happy Mohamed

Mon Jul 17, 2023

Reported Earlier, ProMIS Showcases Preclinical Data At The Alzheimer's Association International Conference 2023 On Computationally-Derived Antibody And Vaccine From Alzheimer's Pipeline

New findings highlight that PMN310 was able to target toxic amyloid-beta oligomers more selectively than other amyloid-beta-directed antibodies which were generated using synthetic oligomers Rationally
Lisa Levin

Mon Jul 10, 2023

Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Gainers Mobilicom Limited (NASDAQ: MOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the U.S. Department of Defense.
Happy Mohamed

Mon May 8, 2023

ProMIS Neurosciences Announces FDA Clearance Of Investigational New Drug Application For PMN310 In Alzheimer's Disease

In preclinical studies, PMN310 demonstrated the ability to selectively target and protect against pathogenic Aβ oligomers The IND clearance of PMN310 in
Benzinga Newsdesk

Mon Apr 10, 2023

ProMIS Neurosciences Announces Submission Of Investigational New Drug Application For Lead Antibody PMN310
Happy Mohamed

Wed Mar 29, 2023

ProMIS Neurosciences Inc. PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared To Other Amyloid-Beta-Directed Antibodies In Poster Presentation At AD/PD 2023

ProMIS Neurosciences Inc. (TSX:PMN) (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as
Happy Mohamed

Thu Mar 9, 2023

Reported Late Wednesday March 08, ProMIS Neurosciences Announces FY22 Financial Results And Recent Highlights; Cash And Cash Equivalents Were $5.9M As Of December 31, 2022 Vs $16.9M YoY

Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration Preclinical data that further characterize ongoing programs, including PMN310, to be presented
Benzinga Newsdesk

Mon Nov 14, 2022

ProMIS Neurosciences Q3 EPS $(0.85) Down From $(0.20) YoY

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.85) per share. This is a 325 percent decrease over losses of $(0.20) per share from the same period last year.
Lisa Levin

Thu Sep 29, 2022

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
Lisa Levin

Wed Sep 28, 2022

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session

Gainers

BABA $76.74 USD

UPRO $48.23 USD

CRNC $17.66 USD

TSLA $248.31 USD

ESLT $207.60 USD

RIOT $12.79 USD

SPOT $182.60 USD

COIN $128.19 USD

TSLL $14.93 USD